|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1995; 26:947-954 © 1995 by the American College of Cardiology Foundation |
Blackpool Victoria Hospital, England, United Kingdom.
OBJECTIVES. We sought to determine whether 12,500 IU of unfractionated heparin given subcutaneously twice daily for 4 months after percutaneous transluminal coronary angioplasty beneficially influences the subsequent rate of angiographic restenosis and the incidence of clinical events. BACKGROUND. Heparin has been shown to exhibit powerful antiproliferative effects against smooth muscle cells in several animal models. METHODS. A randomized trial with blinded data analysis was undertaken to assess the effect of unfractionated subcutaneous heparin on angiographic restenosis after coronary angioplasty. After successful angioplasty, patients were randomized to receive no heparin or 12,500 IU of heparin given subcutaneously twice daily for 4 months. Quantitative coronary angiography was performed before angioplasty, immediately after angioplasty and at follow-up ("early" [before 4 months] or electively [at 4 months]). RESULTS. The study group comprised 339 patients, 167 randomly assigned to receive heparin, 172 to receive no heparin. Repeat cardiac catheterization was performed in 90% of randomized patients. At early and elective restudy (mean 4.2 months), the mean +/- SD difference in minimal lumen diameter between the postangioplasty and follow-up measurement was -0.55 +/- 0.58 mm for the no heparin group and -0.43 +/- 0.59 mm for the heparin group (p = NS). Clinical events during the follow-up period did not differ significantly between groups: fatal myocardial infarction (1 patient in each group), coronary bypass grafting (5 patients in each group), repeat angioplasty (12 in the no heparin, 6 in the heparin group), angina at 4-month assessment (33% in the no heparin, 32% in the heparin group). CONCLUSIONS. Long-term treatment with high dose subcutaneous heparin (12,500 IU twice daily) for 4 months did not favorably influence angiographic or clinical outcome after coronary angioplasty.
This article has been cited by other articles:
|
|
 |
|
  A. M Franks and S. F Gardner AGI-1067: A Novel Vascular Protectant for Prevention of Restenosis Ann. Pharmacother., January 1, 2006; 40(1): 66 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Wohrle, E Al-Khayer, U Grotzinger, C Schindler, M Kochs, V Hombach, and M Hoher Comparison of the heparin coated vs the uncoated Jostent(R)--no influence on restenosis or clinical outcome Eur. Heart J., October 1, 2001; 22(19): 1808 - 1816. [Abstract] [PDF]
|
|
|
|
 |
|
 G. G Nenci and A. Minciotti Low molecular weight heparins for arterial thrombosis Vascular Medicine, November 1, 2000; 5(4): 251 - 258. [Abstract] [PDF]
|
|
|
|
 |
|
 P.A. Underwood and S. M. Mitchell Low density lipoproteins in human plasma make vascular smooth muscle cells resistant to growth inhibition by heparin Cardiovasc Res, September 1, 2000; 47(4): 749 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Verstraete, C. R. M. Prentice, M. Samama, and R. Verhaeghe A European View on the North American Fifth Consensus on Antithrombotic Therapy Chest, June 1, 2000; 117(6): 1755 - 1770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Baron, A. H. Gershlick, K. Hogrefe, J. Armstrong, C. M. Holt, R. K. Aggarwal, M. Azrin, M. Ezekowitz, and D. P. de Bono In vitro evaluation of c7E3-Fab (ReoProTM) eluting polymer-coated coronary stents Cardiovasc Res, June 1, 2000; 46(3): 585 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gershlick Endovascular manipulation to restrict restenosis Vascular Medicine, August 1, 1998; 3(3): 177 - 188. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Rubartelli, L. Niccoli, E. Verna, C. Giachero, M. Zimarino, A. Fontanelli, C. Vassanelli, L. Campolo, E. Martuscelli, G. Tommasini, et al. Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial J. Am. Coll. Cardiol., July 1, 1998; 32(1): 90 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lafont and D. Faxon Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res, July 1, 1998; 39(1): 50 - 59. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Lablanche, E. P. McFadden, N. Meneveau, J. R. Lusson, B. Bertrand, J.-P. Metzger, V. Legrand, G. Grollier, C. Macaya, B. de Bruyne, et al. Effect of Nadroparin, a Low-Molecular-Weight Heparin, on Clinical and Angiographic Restenosis After Coronary Balloon Angioplasty : The FACT Study Circulation, November 18, 1997; 96(10): 3396 - 3402. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. D. Kugelmass and G. E. Raskob Antithrombotic Therapy in Patients Undergoing Coronary Angioplasty or Coronary Stent Placement Clinical and Applied Thrombosis/Hemostasis, October 1, 1997; 3(1_suppl): S24 - S31. [PDF]
|
|
|
|
 |
|
 L. Capron, J. Jarnet, D. Heudes, D. Joseph-Monrose, and P. Bruneval Repeated Balloon Injury of Rat Aorta : A Model of Neointima With Attenuated Inhibition by Heparin Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1649 - 1656. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Cairns, J. Gill, B. Morton, R. Roberts, M. Gent, J. Hirsh, D. Holder, K. Finnie, J. F. Marquis, S. Naqvi, et al. Fish Oils and Low-Molecular-Weight Heparin for the Reduction of Restenosis After Percutaneous Transluminal Coronary Angioplasty: The EMPAR Study Circulation, October 1, 1996; 94(7): 1553 - 1560. [Abstract] [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
